Medical weight management to improve sleep apnea and overall health
About This Service
As part of our comprehensive approach to obstructive sleep apnea care, we offer medical weight management services. Excess weight is a leading contributor to sleep apnea, and meaningful weight loss can significantly improve symptoms and reduce disease severity. We prescribe GLP-1 and GIP receptor agonist medications that have been shown to support substantial, sustained weight loss when combined with lifestyle modifications. Notably, Zepbound (tirzepatide) is FDA-approved for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, making it the first medication approved specifically to address OSA. In clinical trials, patients treated with tirzepatide experienced significant reductions in apnea-hypopnea index (AHI) events and meaningful weight loss compared to placebo.
Patients with obesity, particularly those whose weight contributes to obstructive sleep apnea or other pulmonary conditions. Excess weight compresses the chest wall and upper airway, directly worsening breathing during sleep and reducing lung capacity during the day. This service is also appropriate for patients who have not achieved adequate weight loss through diet and exercise alone and may benefit from medication-assisted treatment.
Reviewed by Dr. Jerry Hsieh, MD — Board Certified in Pulmonary Medicine, Critical Care Medicine, and Internal Medicine
Last reviewed:
Common Questions
How does weight loss improve sleep apnea?
Excess weight — especially around the neck, chest, and abdomen — narrows the upper airway, reduces lung volumes, and worsens the collapse of the airway during sleep. Even modest weight loss (5–10% of body weight) can meaningfully reduce the apnea-hypopnea index (AHI) and OSA severity. Substantial weight loss can eliminate the need for CPAP in some patients with mild-to-moderate OSA.
What is Zepbound (tirzepatide) and how does it work?
Zepbound is the brand name for tirzepatide, a once-weekly injectable medication that activates both the GLP-1 and GIP incretin receptors. These hormones increase satiety, slow gastric emptying, and improve glucose regulation. In December 2024, the FDA approved Zepbound as the first medication specifically indicated for moderate-to-severe obstructive sleep apnea in adults with obesity, based on trials showing substantial reductions in both AHI and body weight.
Who is a candidate for GLP-1 or GIP-receptor medications?
Adults with a BMI of 30 or higher, or 27 or higher with weight-related conditions such as obstructive sleep apnea, type 2 diabetes, hypertension, or cardiovascular disease. These medications are most effective when combined with dietary changes, increased physical activity, and ongoing medical follow-up. Dr. Hsieh evaluates your medical history, current medications, and goals to determine the right option for you.
What are the common side effects?
The most common side effects are gastrointestinal — nausea, decreased appetite, constipation, or diarrhea — which usually improve as the body adjusts and the dose is increased gradually. Less common but more serious risks include pancreatitis, gallbladder problems, and changes in kidney function. Dr. Hsieh reviews the risks and contraindications with you before starting therapy and monitors for side effects at each follow-up.
Will insurance cover weight-loss medications?
Coverage varies significantly by plan. Many commercial insurers cover GLP-1/GIP medications when prescribed for an FDA-approved indication you qualify for, such as obesity with sleep apnea or type 2 diabetes. Medicare currently does not cover medications prescribed solely for weight loss but may cover them for specific approved conditions. We can help you check coverage and explore manufacturer savings programs.
Schedule an Appointment
Contact our office or request an appointment online to get started.
